Company Announcement no. 5/2026 (May 07, 2026 at 13:12:00 CEST)
Revenue increased 8% Y-o-Y in Q1 to DKK 1.3 million, and net loss decreased by 6% to DKK 2.6 million
BIRKERØD, DENMARK - ViroGates A/S ("ViroGates" or the "Company"), a medical technology company developing blood tests for measuring chronic inflammation at health clinics and hospitals, announces its Interim Report for the period 1 January - 31 March 2026, as approved today by the Company's Board of Directors. The report is unaudited.
In Q1 2026, ViroGates experienced increased customer activity, reflecting its conversion to targeting the health and longevity segment. Revenue for the first three months, Q1 2026, reached DKK 1.3 million (Q1 2025: DKK 1.2 million). Operating loss increased to DKK 2.9 million (Q1 2025: DKK 2.8 million), while net loss decreased 6%, ending at DKK 2.6 million.
Major developments included further progress in collaboration with Austrian partner GENSPEED Biotech GmbH on the development of a full-blood suPAR measurement product (suPARnostic® POC+), as well as work on a De Novo application to the US Food and Drug Administration (FDA) with Swedish partner Swedish Orphan Biovitrum AB (publ) ("Sobi") for the suPARnostic® TurbiLatex product.
After the end of the reporting period, ViroGates filed the application, cf. Company Announcement No. 3-2026 dated 8 April 2026. FDA will now commence the review of the file and will likely revert to ViroGates during Q2-Q3 2026 with questions. FDA clearance of suPARnostic® TurbiLatex is part of ViroGates' contractual commitment to Sobi, following a FDA request made in connection with the emergency use authorization for Sobi's Kineret® (anakinra) product.
ViroGates continues to balance support for existing customers in acute care and research with the development of capabilities and partners within the preventive health and longevity market. ViroGates witnessed continued progress in the volume of sales from the preventive health and longevity segment during Q1 2026.
By the end of Q1 2026, ViroGates reports 20 recurring customers (defined as customers who have placed at least 2 orders with a cumulative value of 10,000 EUR or more in the past 12 months). This is unchanged from the same period last year; however, the demographics of recurring customers have shifted in favor of longevity accounts.
ViroGates restates its guidance, expecting full-year revenue between DKK 6 to 7 million and an EBIT of DKK -10 to -12 million in 2026.
Jakob Knudsen, CEO of ViroGates, says: "We are encouraged by the growth in sales within the preventive health and longevity segment, reflecting our strategic focus on this market. While more work remains to establish suPARnostic® as the biomarker of choice for measuring chronic inflammation and biological age, we are confident that our commercial efforts will continue to drive revenue growth.
I am personally very proud that, shortly after the reporting period, we successfully filed a De Novo application with the FDA. An important milestone for any organization, but particularly remarkable for a company of ViroGates' size.
We also remain confident in the potential of an optimized suPARnostic® POC+ with our partner GENSPEED. At the same time, we must ensure the product fully meets regulatory requirements before finalization, and we expect to provide further updates during Q2 2026."
Financial results in Q1 2026 (Q1 2025 results in brackets)
- Revenue increased by 8% to TDKK 1,303 (TDKK 1,202)
- Operating expenses increased by 17% to TDKK -3,846 (TDKK -3,285)
- Operating loss increased by 4% to TDKK -2,871 (TDKK -2,753)
- Net loss decreased by 6% to TDKK -2,611 (TDKK -2,784)
- Cash and cash equivalents at the end of the period amounted to TDKK 22,280 (TDKK 11,226)
Business highlights in Q1 2026
- Continued the work on the suPARnostic® POC+ with GENSPEED Biotech GmbH
- Compiled a De Novo application for the FDA and subsequently filed it with the FDA
- Grew sales within the preventive health and longevity customer segment
- Reported a recurring customer base of 20 customers (equal to the same period last year).
This announcement is a summary and should be read with ViroGates' Q1 2026 report, published on 7 May 2026. A downloadable PDF version is available on ViroGates' website.
For further information, please contact:
ViroGates A/S:
CEO, Jakob Knudsen
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance AB
Per Lönn
Tel. (+46) 40 200 250 | Email: per.lonn@vhcorp.se
About ViroGates
ViroGates A/S is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals to improve patient care. ViroGates markets its blood test products under the suPARnostic® brand.
The company was founded in 2000. Headquartered in Denmark, ViroGates' sales force covers Spain, France, and Benelux, while distributors serve other markets. ViroGates' shares (ticker "VIRO") are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.
